Skip to main navigation
Skip to search
Skip to main content
Korea University Pure Home
Home
Profiles
Research units
Equipment
Research output
Press/Media
Search by expertise, name or affiliation
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi
, Soo Mee Bang
, Seongsoo Jang
, Chul Won Jung
, Hee Jin Kim
, Ho Young Kim
, Soo Jeong Kim
, Yeo Kyeoung Kim
, Jinny Park
, Jong Ho Won
*
*
Corresponding author for this work
Department of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
23
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Guidelines for the management of myeloproliferative neoplasms'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myeloproliferative Neoplasms
100%
Genetic mutation
28%
Janus Kinase 2 (JAK2)
28%
New Genetics
28%
Diagnostic Criteria
14%
Novel Therapeutics
14%
Pathophysiology
14%
New Targets
14%
New Drugs
14%
Treatment Strategy
14%
Korean Society
14%
Survival Benefit
14%
Intermediate Risk
14%
Polycythemia Vera
14%
Epidemiology
14%
Randomized Controlled Trial
14%
Clinical Investigation
14%
Hematology
14%
Drug Development
14%
Janus Kinase 1 (JAK1)
14%
Myelofibrosis
14%
Genetic Aberrations
14%
Essential Thrombocythemia
14%
Working Party
14%
Expert Panel
14%
Diagnostic Guidelines
14%
Primary Myelofibrosis
14%
Criteria for Diagnosis
14%
Diagnostic Standards
14%
JAK Inhibitors
14%
Ruxolitinib
14%
Symptom Benefit
14%
Philadelphia Chromosome-negative
14%
Therapeutic Guidelines
14%
Medicine and Dentistry
Myeloproliferative Neoplasm
100%
Diagnosis
28%
Gene Mutation
28%
Janus Kinase 2
28%
Pathophysiology
14%
Cohort Effect
14%
Randomized Controlled Trial
14%
Hematology
14%
Polycythemia vera
14%
Myelofibrosis
14%
Myeloid metaplasia
14%
Essential Thrombocythaemia
14%
Janus Kinase Inhibitor
14%
Ruxolitinib
14%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloproliferative Neoplasm
100%
Janus Kinase 2
28%
Pathophysiology
14%
Drug Development
14%
Randomized Controlled Trial
14%
Myelofibrosis
14%
Myeloid metaplasia
14%
Janus Kinase Inhibitor
14%
Thrombocythemia
14%
Ruxolitinib
14%
Polycythemia vera
14%